Your browser is no longer supported. Please, upgrade your browser.
Taiwan Liposome Company, Ltd.
Index- P/E- EPS (ttm)-0.51 Insider Own- Shs Outstand42.08M Perf Week-7.68%
Market Cap207.44M Forward P/E- EPS next Y-0.76 Insider Trans- Shs Float36.60M Perf Month-7.04%
Income- PEG- EPS next Q-0.19 Inst Own0.19% Short Float0.00% Perf Quarter13.07%
Sales- P/S- EPS this Y17.00% Inst Trans- Short Ratio0.00 Perf Half Y8.35%
Book/sh0.24 P/B20.54 EPS next Y-4.10% ROA- Target Price- Perf Year4.89%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.48 - 12.65 Perf YTD11.29%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-61.03% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low98.79% ATR0.33
Employees- Current Ratio- Sales Q/Q1.10% Oper. Margin- RSI (14)39.86 Volatility7.38% 5.29%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.25 Prev Close4.90
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume26.11K Price4.93
Recom2.00 SMA20-10.89% SMA50-1.83% SMA200-1.67% Volume32,565 Change0.61%
Dec-23-19Resumed Cantor Fitzgerald Overweight $11
Jun-21-19Initiated Robert W. Baird Outperform
Dec-17-18Initiated Laidlaw Buy
Dec-17-18Initiated Janney Buy
Dec-17-18Initiated H.C. Wainwright Buy
Mar-02-21 04:00AM  
Feb-05-21 04:15AM  
Jan-04-21 05:00AM  
Dec-28-20 04:00AM  
Dec-18-20 04:00AM  
Nov-03-20 07:38AM  
Oct-28-20 04:51AM  
Oct-21-20 04:45AM  
Oct-14-20 04:41AM  
Oct-06-20 11:53PM  
Sep-21-20 03:30PM  
Sep-11-20 04:45AM  
Sep-09-20 05:00AM  
Sep-03-20 05:00AM  
Aug-26-20 05:40AM  
Aug-14-20 06:30AM  
Aug-05-20 05:00AM  
Jul-15-20 07:23AM  
Jun-30-20 05:00AM  
May-31-20 12:09AM  
May-18-20 02:53AM  
May-13-20 04:12AM  
May-04-20 05:48AM  
Apr-27-20 08:30AM  
Feb-12-20 04:00AM  
Feb-11-20 05:45AM  
Jan-08-20 04:00AM  
Jan-02-20 04:00AM  
Nov-27-19 04:30AM  
Nov-22-19 07:23AM  
Oct-24-19 05:00AM  
Oct-22-19 06:09AM  
Oct-21-19 05:24AM  
Oct-20-19 04:10AM  
Oct-07-19 04:30AM  
Oct-01-19 04:30AM  
Sep-23-19 05:00AM  
Sep-03-19 06:04AM  
Aug-28-19 05:00AM  
Jul-30-19 06:04AM  
Jun-25-19 05:00AM  
Jun-14-19 04:45AM  
Jun-12-19 05:00AM  
May-08-19 07:07AM  
May-06-19 06:00AM  
May-02-19 06:00AM  
Apr-22-19 04:00AM  
Apr-15-19 05:00AM  
Apr-08-19 05:00AM  
Apr-01-19 05:00AM  
Mar-25-19 05:00AM  
Mar-18-19 05:00AM  
Mar-11-19 06:27AM  
Mar-03-19 09:57PM  
Jan-25-19 03:53AM  
Jan-22-19 06:00AM  
Dec-18-18 05:30AM  
Nov-25-18 06:00AM  
Nov-21-18 04:39AM  
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site. The company provides various product candidates that target various areas of unmet medical need in pain management, ophthalmology, and oncology. Its lead product candidate is TLC599, an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP), which is in Phase III trial for knee osteoarthritis pain. The company's product candidates also comprises TLC590, a non-opioid BioSeizer formulation of the API ropivacaine that is in Phase II clinical trial for post-surgical pain management; TLC399, a multilamellar and multivesicular BioSeizer formulation of DSP, which is in Phase II clinical trial for ophthalmology indications; and TLC178, an API that is in Phase I/II dose escalation trial to treat rhabdomyosarcoma. Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei, Taiwan.